CY1114911T1 - Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινης και [1,2,4]τριαζολο[1,5-c]πυριμιδινης και χρηση αυτων - Google Patents

Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινης και [1,2,4]τριαζολο[1,5-c]πυριμιδινης και χρηση αυτων

Info

Publication number
CY1114911T1
CY1114911T1 CY20141100147T CY141100147T CY1114911T1 CY 1114911 T1 CY1114911 T1 CY 1114911T1 CY 20141100147 T CY20141100147 T CY 20141100147T CY 141100147 T CY141100147 T CY 141100147T CY 1114911 T1 CY1114911 T1 CY 1114911T1
Authority
CY
Cyprus
Prior art keywords
compounds
trizolo
tyrosine kinase
receptor tyrosine
axl receptor
Prior art date
Application number
CY20141100147T
Other languages
English (en)
Inventor
Grégoire Alexandre Pavé
James Donald Firth
Lorna Stewart
Laurent Jean Martin Rigoreau
Emma Louise Wynne
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38787938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114911(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1114911T1 publication Critical patent/CY1114911T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Η παρούσα εφεύρεση αφορά γενικώς στο πεδίο θεραπευτικών ενώσεων και ειδικότερα σε ορισμένες τριάζολο ενώσεις (που αναφέρονται εδώ ως ΤΑΖ ενώσεις) και ειδικώς ορισμένες ενώσεις [1,2,4]τριαζολο[1,5-a]πυριδίνης και [1,2,4]τριαζολο[1,5-c]πυριμιδίνης, οι οποίες, inter alia, παρεμποδίζουν λειτουργία κινάσης τυροσίνης υποδοχέα AXL. Η παρούσα εφεύρεση αφορά επίσης σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις και τη χρήση τέτοιων ενώσεων και συνθέσεων, τόσο in vitro όσο και in vivo, για να αναστέλλεται λειτουργία κινάσης τυροσίνης υποδοχέα AXL και στη θεραπεία ασθενειών και καταστάσεων που προκαλούνται από κινάση τυροσίνης υποδοχέα AXL, που βελτιώνονται με την αναστολή της λειτουργίας κινάσης τυροσίνης υποδοχέα AXL, κ.λπ., που συμπεριλαμβάνουν πολλαπλασιαστικές καταστάσεις, όπως καρκίνο, κ.λπ.
CY20141100147T 2007-10-10 2014-02-24 Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινης και [1,2,4]τριαζολο[1,5-c]πυριμιδινης και χρηση αυτων CY1114911T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97879207P 2007-10-10 2007-10-10
GBGB0719803.9A GB0719803D0 (en) 2007-10-10 2007-10-10 Therapeutic compounds and their use
EP08806565.1A EP2217578B9 (en) 2007-10-10 2008-10-10 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use

Publications (1)

Publication Number Publication Date
CY1114911T1 true CY1114911T1 (el) 2016-12-14

Family

ID=38787938

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100147T CY1114911T1 (el) 2007-10-10 2014-02-24 Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινης και [1,2,4]τριαζολο[1,5-c]πυριμιδινης και χρηση αυτων

Country Status (11)

Country Link
US (4) US8431596B2 (el)
EP (1) EP2217578B9 (el)
CY (1) CY1114911T1 (el)
DK (1) DK2217578T5 (el)
ES (1) ES2446298T3 (el)
GB (1) GB0719803D0 (el)
HR (1) HRP20140191T1 (el)
PL (1) PL2217578T3 (el)
PT (1) PT2217578E (el)
SI (1) SI2217578T1 (el)
WO (1) WO2009047514A1 (el)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2561104C2 (ru) * 2008-06-20 2015-08-20 Дженентек, Инк. Триазолопиридиновые соединения-ингибиторы jak и способы
RU2560153C2 (ru) 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TW201010977A (en) * 2008-08-12 2010-03-16 Takeda Pharmaceutical Amide compound
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
AU2011211410B2 (en) * 2009-02-13 2013-01-31 Fovea Pharmaceuticals Sa [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors
PE20120110A1 (es) * 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
MX2011012961A (es) * 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
MX350217B (es) * 2010-05-25 2017-08-30 Dow Agrosciences Llc Proceso para la preparacion de 8-alcoxi [1,2,4] triazol [1,5-c] pirimidin-2-aminas substituidas-5.
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
AU2011295440B2 (en) 2010-08-27 2015-06-11 Merck Patent Gmbh Triazolopyrazine derivatives
EP2648728B1 (en) * 2010-12-06 2016-04-27 Cephalon, Inc. Janus kinase 2 (jak2) inhibitor for the treatment of lupus
AU2012244859B2 (en) * 2011-04-21 2017-06-08 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
PL2810937T3 (pl) * 2012-01-31 2017-07-31 Daiichi Sankyo Company, Limited Pochodna pirydonu
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
BR112016012146B1 (pt) 2013-11-27 2022-11-01 Signalchem Lifesciences Corporation Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
HUE045725T2 (hu) 2014-02-13 2020-01-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
AU2015217073B2 (en) 2014-02-13 2019-08-22 Incyte Holdings Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN103965202B (zh) * 2014-05-21 2016-01-20 邹宏丽 二环稠合杂环化合物、其制备方法及用途
TW201613919A (en) * 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MX2017009449A (es) 2015-01-20 2018-05-28 Wuxy Fortune Pharmaceutical Co Ltd Inhibidor jak.
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
JP6600365B2 (ja) 2015-04-29 2019-10-30 无▲錫▼福祈制▲薬▼有限公司 Ｊａｋ阻害剤
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
DK3305788T3 (da) 2015-05-29 2020-09-28 Wuxi Fortune Pharmaceutical Co Ltd Janus-kinase-hæmmer
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
MX2018005342A (es) * 2015-11-02 2018-08-15 Janseen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo.
US20190099413A1 (en) 2016-02-26 2019-04-04 Ono Pharmaceutical Co., Ltd. Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
CA3019145A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
EP3445339B1 (en) 2016-04-22 2023-08-23 Incyte Corporation Formulations of an lsd1 inhibitor
CN106188041B (zh) * 2016-06-29 2017-12-08 四川大学华西医院 [1,2,4]三唑并[1,5‑a]吡啶衍生物
WO2018000549A1 (zh) * 2016-06-29 2018-01-04 四川大学华西医院 [1,2,4]三唑并[1,5-a]吡啶衍生物及其晶型
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN109963851B (zh) * 2016-10-26 2021-11-30 詹森药业有限公司 融合的双环吡啶化合物及其作为ampa受体调节剂的用途
AU2017350688B2 (en) * 2016-10-26 2021-04-01 Rapport Therapeutics, Inc. Fused azaheterocyclic compounds and their use as AMPA receptor modulators
EP3535269B1 (en) 2016-11-02 2020-12-09 Janssen Pharmaceutica NV [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
JP7018944B2 (ja) 2016-11-02 2022-02-14 ヤンセン ファーマシューティカ エヌ．ベー． ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン化合物
CA3041412A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
US20200197385A1 (en) 2017-08-23 2020-06-25 Ono Pharmaceutical Co., Ltd. Therapeutic agent for cancer containing axl inhibitor as active ingredient
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
JP2021529765A (ja) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ａｘｌ／ｍｅｒ阻害剤の製剤
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US20220185810A1 (en) * 2019-03-30 2022-06-16 Unichem Laboratories Limited Novel Process for the Preparation of Filgotinib and Intermediates Thereof
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
CN111892592B (zh) * 2019-08-06 2023-09-19 江苏柯菲平医药股份有限公司 Jak激酶抑制剂及其用途
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN115819425A (zh) * 2022-12-22 2023-03-21 五邑大学 一种三唑并六元氮杂环-2-胺类化合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL105768C (el) 1959-02-25
US3053844A (en) 1959-04-13 1962-09-11 Ici Ltd Mono-acyl derivatives of s-triazolo [2, 3-c] pyrimidines
GB873223A (en) 1959-04-13 1961-07-19 Ici Ltd Heterocyclic compounds
US3046276A (en) 1959-06-15 1962-07-24 Ici Ltd S-triazolo-[2, 3-c] pyrimidine derivatives
GB897870A (en) 1959-06-15 1962-05-30 Ici Ltd s-triazolo[2, 3-c]pyrimidine derivatives
US2963480A (en) 1959-12-29 1960-12-06 Edward C Taylor 6-pteridinehydrazine and amidrazone derivatives
US4579848A (en) * 1983-07-28 1986-04-01 American Cyanamid Company 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines
NZ208996A (en) * 1983-07-28 1989-08-29 American Cyanamid Co 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
JPH04204441A (ja) 1990-11-29 1992-07-24 Konica Corp 新規な染料を含有するハロゲン化銀写真感光材料
US5358950A (en) 1991-07-05 1994-10-25 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists
FR2678618B1 (fr) 1991-07-05 1993-11-05 Upsa Laboratoires Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE69705821T2 (de) 1996-09-24 2001-11-08 Dow Agrosciences Llc N-((1,2,4)triazoloazinyl)benzolsulfonamid- und pyridinsulfonamidverbindungen und deren verwendung als herbizide
JPH10148903A (ja) 1996-11-20 1998-06-02 Konica Corp 耐圧性の改良されたハロゲン化銀写真感光材料
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
JP2003213152A (ja) 2002-01-23 2003-07-30 Konica Corp 着色組成物、着色微粒子分散物、インクジェット用インク及びインクジェット記録方法
AU2004220234C1 (en) 2003-02-13 2013-01-17 Msd K.K. Novel 2-pyridinecarboxamide derivatives
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
PT1648899E (pt) 2003-07-25 2007-03-30 Neurogen Corp Imidazo-pirimidinas e triazolo-pirimidinas: ligandos do receptor de benzodiazepina
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
WO2005018532A2 (en) 2003-08-25 2005-03-03 Actar Ab Purine receptor binding compounds
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
JP4204441B2 (ja) 2003-10-31 2009-01-07 ゲイツ・ユニッタ・アジア株式会社 寿命予知可能なタイミングベルト及びその製造方法
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
EP1807417A2 (en) 2004-11-04 2007-07-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
TW200638882A (en) 2005-02-04 2006-11-16 Senomyx Inc Molecules comprising linked organic moieties as flavor modifiers for comestible compositions
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
CA2662074A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EP1894931A1 (en) 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2561104C2 (ru) 2008-06-20 2015-08-20 Дженентек, Инк. Триазолопиридиновые соединения-ингибиторы jak и способы
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية

Also Published As

Publication number Publication date
US20150246915A1 (en) 2015-09-03
EP2217578A1 (en) 2010-08-18
SI2217578T1 (sl) 2014-03-31
PL2217578T3 (pl) 2014-05-30
US20100298339A1 (en) 2010-11-25
US8431596B2 (en) 2013-04-30
PT2217578E (pt) 2014-02-17
DK2217578T3 (da) 2014-02-03
ES2446298T9 (es) 2014-09-29
EP2217578B9 (en) 2014-09-10
WO2009047514A1 (en) 2009-04-16
ES2446298T3 (es) 2014-03-07
US20170066762A1 (en) 2017-03-09
GB0719803D0 (en) 2007-11-21
HRP20140191T1 (hr) 2014-04-25
EP2217578B1 (en) 2013-12-04
US20140155594A1 (en) 2014-06-05
DK2217578T5 (da) 2014-11-10
US9771362B2 (en) 2017-09-26
US9394301B2 (en) 2016-07-19
US9012633B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
CY1114911T1 (el) Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινης και [1,2,4]τριαζολο[1,5-c]πυριμιδινης και χρηση αυτων
CY1121338T1 (el) Χρηση αλατων του αναστολεα kinασης janus (r)-3-(4-(7h-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλο)-3-κυκλοπεντυλο- προπανονιτριλιο
CY1122425T1 (el) 3-[4-(7η-πυρρολο[2,3-d]πυριμιδιν-4-υλο)-1η-πυραζολ-1-υλ]οκτανο-ή επτανονιτριλιο ως αναστολεις jak
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
CY1117180T1 (el) Ενωσεις φαινυλ amino πυριμιδινης και χρησεις αυτων
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
CY1115107T1 (el) ΕΝΩΣΕΙΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΩΝ ΙΜΙΔΑΖΟ[1,2-b]ΠΥΡΙΔΑΖΙΝΩΝ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ TRK
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
EA201100450A1 (ru) Макроциклические пирамидины в качестве ингибиторов протеинкиназы
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
CR9929A (es) Nuevos compuestos
TN2014000255A1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
CL2009000405A1 (es) Compuestos derivados de pirrolo [2,3 b] pirazina, inhibidores jak y cyk; y sus usos en el tratamiento de enfermedades inflamatorias, autoinmune y cancer.
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA201290878A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2012000513A (es) Compuestos pirazolo[1,5-a]pirimidina substituidos como inhibidores de trk cinasa.
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
NZ596301A (en) Novel 7-deazapurine nucleosides for therapeutic uses